Drugs / LB-DTK-CMV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07679412 | Apr 2026 → Aug 2027 expected | cytomegalovirus retinitis | LucasBio | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB-DTK-CMV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07679412 ↗ |
| Modality | Cell therapy | “LB-DTK-CMV is a CMV-specific T cell therapy product derived from a patient (autologous)” NCT07679412 ↗ |